Methods of using vesicant drug formulations
OwnerAvner Ramuinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating, as well as preventing extravasation injury. In particular, the present invention pertains to photochemotherapeutic methods of prophylaxis and/or treatment of extravasation injury induced by vesicant antineoplastic drugs and other pharmaceutical formulations. In accordance with the present invention, extravasation injury is prevented or minimized by the coadministration of photoinactivation inducing compounds in a formulation comprising a vesicant antineoplastic or other pharmaceutical formulation, and subsequently exposing the injection or infusion site to photoexciting light.
Claims18
A method of treatment, comprising:
- a) providing:
- i) a subject;
- and
- ii) a formulation comprising at least one photoinactivation-inducing compound, wherein said photoinactivation-inducing compound comprises at least one photosensitizer selected from the group consisting of flavins, benz[γ]isoquinoline,5,10-dione, and 9(10)-anthraquinone-2-sulfonic acid, quinolines, non-steroidal anti-inflammatory compounds, aromatic alcohols, aromatic acids, xanthene, indoles, naphthaldehydes, naphthones, benzophenones, anthrones, xanthrones, acridones, anthraquinones, pyridines, pyrroles, thiophenes, phenyl-2-furyl ketones, thienyl ketones, chromanones, coumaranones, 4-chromones, coumarins, carbolines, lumazines, alloxazines, lumichromes, hydroxy groups, amino groups, methoxy groups, aliphatic groups, phenyl groups, thiol groups, nitro groups, carboxyl groups, acetyl groups, acetate groups, phenoxy groups, benzyloxy groups, chloro groups, fluoro groups, oxo groups, fluorene groups, indole groups, isoindole groups, xanthine groups, sulfonyl groups, dioxane groups, furyl groups, thienyl groups, aza groups, anthracene groups, naphthyl groups, naphthyloxy groups, naphythylthio groups, acetonitrile groups, acetamide groups, acetoxy groups, benzyl groups, benzoyl groups, and sulfonic acid groups, and derivatives thereof;
- b) administering intravenously said formulation to said subject;
- and
- c) exposing the intravenous administration site to UVA light.
A method of treatment, comprising:
- a) providing:
- i) a subject;
- and
- ii) a formulation comprising riboflavin and a photoenhancer selected from the group consisting of 3-(4-methoxyphenyl)-1-propanol, and histidine;
- b) administering intravenously said formulation to said subject;
- and
- c) exposing the intravenous administration site to UVA light.
A composition comprising a serum-free saline solution comprising a vesicant chemotherapeutic and a photoinactivation inducing compound selected from the group consisting of flavins, benz[γ]isoquinoline,5,10-dione, and 9(10)-anthraquinone-2-sulfonic acid, quinolines, non-steroidal anti-inflammatory compounds, aromatic alcohols, aromatic acids, xanthene, indoles, naphthaldehydes, naphthones, benzophenones, anthrones, xanthrones, acridones, anthraquinones, pyridines, pyrroles, thiophenes, phenyl-2-furyl ketones, thienyl ketones, chromanones, coumaranones, 4-chromones, coumarins, carbolines, lumazines, alloxazines, lumichromes, hydroxy groups, amino groups, methoxy groups, aliphatic groups, phenyl groups, thiol groups, nitro groups, carboxyl groups, acetyl groups, acetate groups, phenoxy groups, benzyloxy groups, chloro groups, fluoro groups, oxo groups, fluorene groups, indole groups, isoindole groups, xanthine groups, sulfonyl groups, dioxane groups, furyl groups, thienyl groups, aza groups, anthracene groups, naphthyl groups, naphthyloxy groups, naphythylthio groups, acetonitrile groups, acetamide groups, acetoxy groups, benzyl groups, benzoyl groups, and sulfonic acid groups, and derivatives thereof.
Dependencies are inferred from the claim text.